IFNA2 and melanoma: A turning point was a 2020 Phase III trial that demonstrated the superiority of ipilimumab (an anti-CTLA-4 antibody) over high-dose IFN-α2b, shifting the treatment paradigm for operable melanoma towards ICI immunotherapy [193,197].